Extended Data Fig. 5: Molecular profiling of treatment response. | Nature Cancer

Extended Data Fig. 5: Molecular profiling of treatment response.

From: Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial

Extended Data Fig. 5

Box plots showing: A) log2 transformed TMB in good (n = 41 patients) vs poor responders (n = 12 patients) (defined as EOT Ki67 ≥ 10%) in control vs megestrol combination treatment. Two-way ANOVA, with adjusted p-values (Tukey method), B) log transformed EOT Ki67in tumors with SNVs/CNVs in the PI3K/AKT pathway (n = 32/53, defined as predicted driver mutations in PIK3CA, PIK3R1, AKT1, PTEN or deletion of PTEN/PIK3R1) and C) Log transformed EOT Ki67 in tumors with (n = 14)/without (n = 39) amplification of CCND1. Data points are coloured according to whether EOT Ki67 was </≥ 10%. Statistic for panels B + C: two-sided t-test. Boxes = IQR, centres = median, whiskers = min/max (excluding outliers, defined as <Q1 – 1.5*IQR or > Q3 + 1.5*IQR).

Source data

Back to article page